| Douglas C Schafer, PA | |
|
804 S Walnut St, Freeman, SD 57029-0900 | |
| (605) 925-4219 | |
| Not Available |
| Full Name | Douglas C Schafer |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Location | 804 S Walnut St, Freeman, South Dakota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952372336 | NPI | - | NPPES |
| 6820372 | Medicaid | SD | |
| 6820370 | Medicaid | SD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 0171 (South Dakota) | Primary |
| 363AM0700X | Physician Assistant - Medical | (* (Not Available)) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Douglas C Schafer, PA Po Box 900, Freeman, SD 57029-0900 Ph: (605) 925-4219 | Douglas C Schafer, PA 804 S Walnut St, Freeman, SD 57029-0900 Ph: (605) 925-4219 |
News Archive
Can social networking sites help people make wise health decisions? A new study in the Journal of Consumer Research says it depend on people's willingness to take action on the information they gain from the sites.
Countries producing food containing harmful bacteria and toxins could be named and shamed more quickly using a worldwide alert system devised by a team of scientists from Kingston University in South West London. The team, led by Professor Declan Naughton, says the easy to use computer tool can be used to monitor contaminated products; helping to prevent them reaching shop shelves and ensuring that food is safe to eat.
Immunomic Therapeutics, Inc. ("Immunomic Therapeutics"), a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic Therapeutics' vaccine designed to treat allergies induced by Japanese red cedar pollen.
A genetic mutation, known as GBA, that leads to early onset of Parkinson's disease and severe cognitive impairment (in about 4 to 7 percent of all patients with the disease) also alters how specific lipids, ceramides and glucosylceramides are metabolized. Mayo Clinic researchers have found that Parkinson's patients who do not carry the genetic mutation also have higher levels of these lipids in the blood. Further, those who had Parkinson's and high blood levels were also more likely to have cognitive impairment and dementia.
› Verified 5 days ago
Teresa R Behl, PAC Physician Assistant Medicare: Medicare Enrolled Practice Location: 804 Walnut St, Freeman, SD 57029 Phone: 605-925-4219 |